Answers are grounded in this paper and cite their sources.
Nephrotoxicity in patients treated with (177)Lu-octreotate was low. No (sub)acute grade 3 or 4 renal toxicity occurred and none of the patients had an annual decrease in renal function of >20 %. No risk factors for renal toxicity could be identified. Our data support the idea that the radiation dose threshold, adopted from external beam radiotherapy and PRRT with (90)Y-labelled somatostatin analogues, does not seem valid for PRRT with (177)Lu-octreotate.
No takes yet. Share an insight, caveat, or question.
Bergsma et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: